Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy
- Substances:AnastrozoleCamizestrant+6
Spain- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:AstraZeneca AB
Rare diseases
Investigational molecules
Locations
Back to Spain7 clinical trials in Alcoy, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)
Spain
Spain
Spain
Spain
Spain
Spain
SpainThe busiest research cities in the country
What the registry says about research in the country
Groundbreaking studies focusing on triple-negative breast cancer and HER2-positive variants, evaluating innovative combination therapies including immunotherapy approaches.
Research aims to improve survival rates through targeted therapeutic strategies.
Investigation of metastatic colorectal cancer management, with particular focus on preventing complications through prophylactic treatments.
Studies emphasize improving patient outcomes in advanced disease stages.
Advanced research utilizing minimal residual disease monitoring and targeted therapies for various breast cancer subtypes.
Focus on personalized treatment strategies using molecular diagnostics.
Tell us about your condition – we search every trial in Europe and connect you with the right site.